UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Reactive astrocytic S1P3 signaling modulates the blood–tumor barrier in brain metastases

Nature communications, 2018-07, Vol.9 (1), p.2705-18, Article 2705

2018

Volltextzugriff (PDF)

Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma

Clinical cancer research, 2017-08, Vol.23 (16), p.4633-4641

2017

Volltextzugriff (PDF)

Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma

The New England journal of medicine, 2024-06, Vol.390 (23), p.2143-2155

2024

Volltextzugriff (PDF)

Vertical Inhibition of the RAF-MEK-ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRAS Q61X Mutant Rhabdomyosarcoma

Molecular cancer therapeutics, 2022-01, Vol.21 (1), p.170-183

2022

Volltextzugriff (PDF)

Vertical Inhibition of the RAF–MEK–ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant Rhabdomyosarcoma

Molecular cancer therapeutics, 2022-01, Vol.21 (1), p.170-183

2022

Volltextzugriff (PDF)

Treatment with novel topoisomerase inhibitors in Ewing sarcoma models reveals heterogeneity of tumor response

Frontiers in cell and developmental biology, 2024-10, Vol.12

2024

Volltextzugriff (PDF)

A modeling and simulation study of less frequent dosing of nivolumab 480 mg

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.3115-3115

2019

Volltextzugriff (PDF)

Direct injection mass spectrometric confirmation of multiple drugs in overdose cases from postmortem blood using electrospray ionization-tandem mass spectrometry and MS(3)

Journal of analytical toxicology, 2008-10, Vol.32 (8), p.709

2008

Volltextzugriff (PDF)

Abstract A081: Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion

Molecular cancer therapeutics, 2019-12, Vol.18 (12_Supplement), p.A081-A081

2019

Volltextzugriff (PDF)

DIPG-10. A Phase I trial of panobinostat following radiation therapy in children with diffuse intrinsic pontine glioma (DIPG) or H3K27M-mutated thalamic diffuse midline glioma (DMG): Report from the Pediatric Brain Tumor Consortium (PBTC-047)

Neuro-oncology (Charlottesville, Va.), 2022-06, Vol.24 (Supplement_1), p.i19-i20

2022

Volltextzugriff (PDF)

Phase Ib/II Study of Multi-Targeted Therapy with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Blood, 2023-11, Vol.142 (Supplement 1), p.434-434

2023

Volltextzugriff (PDF)

Pharmacogenomic Variation May Impact Cyclophosphamide Metabolism and Graft Status after HCT for Sickle Cell Disease

Transplantation and cellular therapy, 2024-02, Vol.30 (2), p.S457-S457

2024

Volltextzugriff (PDF)

Abstract B047: Phase I trial of αvβ3 integrin cytotoxin ProAgio in patients with previously treated advanced pancreatic cancer and other solid tumor malignancies

Molecular cancer therapeutics, 2023-12, Vol.22 (12_Supplement), p.B047-B047

2023

Volltextzugriff (PDF)

Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion with or without nab-paclitaxel

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3553-3553

2020

Volltextzugriff (PDF)

A phase II trial of the DNA methyl transferase inhibitor, SGI-110 (Guadecitabine), in children and adults with SDH-deficient GIST, pheochromocytoma, and paraganglioma, and HLRCC-associated kidney cancer

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.11540-11540

2020

Volltextzugriff (PDF)

A phase I trial of pomalidomide in combination with liposomal doxorubicin in patients with Kaposi sarcoma with or without other KSHV-associated diseases

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.11552-11552

2020

Volltextzugriff (PDF)

Abstract PR07: Phase I/II study of mesothelin-targeted immunotoxin LMB-100 with nab-paclitaxel for patients with advanced pancreatic adenocarcinoma

Cancer research (Chicago, Ill.), 2019-12, Vol.79 (24_Supplement), p.PR07-PR07

2019

Volltextzugriff (PDF)

Phase I Study of the Immunotoxin LMB-100 in Patients with Mesothelioma and Other Solid Tumors Expressing Mesothelin

Cancer, 2020-09, Vol.126 (22), p.4936-4947

2020

Volltextzugriff (PDF)

Abstract 2943: Severe hepatotoxicity of mithramycin therapy caused by altering expression of hepatocellular bile transporters

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.2943-2943

2019

Volltextzugriff (PDF)

IL-15 by continuous i.v. infusion to adult patients with solid tumors in a Phase I trial induced dramatic NK cell subset expansion

Clinical cancer research, 2019-05, Vol.25 (16), p.4945-4954

2019

Volltextzugriff (PDF)

HSD3B1

The Journal of clinical investigation, 2018-08, Vol.128 (8), p.3333

2018

Volltextzugriff (PDF)

A prospective international randomized phase II study evaluating the food effect on the pharmacokinetics (PK) and pharmacodynamics (PD) of abiraterone acetate (AA) in men with castration-resistant prostate cancer (CRPC)

Journal of clinical oncology, 2017-02, Vol.35 (6_suppl), p.176-176

2017

Volltextzugriff (PDF)

Plasma Protease-Mediated Metabolism of Carfilzomib and Its Implications on Clinical Effects and Side Effects

Blood, 2014-12, Vol.124 (21), p.3476-3476

2014

Volltextzugriff (PDF)

1 – 25 von 56

Suche als RSS-Feed

Aktive Filter

KollektionIngenta.com

ThemaLife Sciences & Biomedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(52)

Publikationsform

Sprache

Englisch
(56)

Erscheinungsjahr

n.n

Thema

Female
(5)
Humans
(5)
Adult
(3)
Animals
(3)
Biological And Medical Sciences
(3)
Cell Line, Tumor
(3)
Middle Aged
(3)
Aged
(2)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(2)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(2)
Apoptosis
(2)
Drug Intoxications. Doping
(2)
Endothelial Cells
(2)
Hemorrhage
(2)
Inflammation
(2)
Male
(2)
Medical Prognosis
(2)
Medical Sciences
(2)
Patients
(2)
Pharmacology. Drug Treatments
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Reactive astrocytic S1P3 signaling modulates the blood–tumor barrier in brain metastases

Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma

Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma

Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the novel NAMPT Inhibitor OT-82

Vertical Inhibition of the RAF-MEK-ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRAS Q61X Mutant Rhabdomyosarcoma

Vertical Inhibition of the RAF–MEK–ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant Rhabdomyosarcoma

Treatment with novel topoisomerase inhibitors in Ewing sarcoma models reveals heterogeneity of tumor response

A modeling and simulation study of less frequent dosing of nivolumab 480 mg

Phase 2 Response-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, and Rituximab (TEDDI-R) for Secondary CNS Lymphoma

Direct injection mass spectrometric confirmation of multiple drugs in overdose cases from postmortem blood using electrospray ionization-tandem mass spectrometry and MS(3)

Abstract A081: Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion

DIPG-10. A Phase I trial of panobinostat following radiation therapy in children with diffuse intrinsic pontine glioma (DIPG) or H3K27M-mutated thalamic diffuse midline glioma (DMG): Report from the Pediatric Brain Tumor Consortium (PBTC-047)

Phase Ib/II Study of Multi-Targeted Therapy with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Pharmacogenomic Variation May Impact Cyclophosphamide Metabolism and Graft Status after HCT for Sickle Cell Disease

Abstract B047: Phase I trial of αvβ3 integrin cytotoxin ProAgio in patients with previously treated advanced pancreatic cancer and other solid tumor malignancies

Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion with or without nab-paclitaxel

A phase II trial of the DNA methyl transferase inhibitor, SGI-110 (Guadecitabine), in children and adults with SDH-deficient GIST, pheochromocytoma, and paraganglioma, and HLRCC-associated kidney cancer

A phase I trial of pomalidomide in combination with liposomal doxorubicin in patients with Kaposi sarcoma with or without other KSHV-associated diseases

Abstract PR07: Phase I/II study of mesothelin-targeted immunotoxin LMB-100 with nab-paclitaxel for patients with advanced pancreatic adenocarcinoma

Phase I Study of the Immunotoxin LMB-100 in Patients with Mesothelioma and Other Solid Tumors Expressing Mesothelin

Abstract 2943: Severe hepatotoxicity of mithramycin therapy caused by altering expression of hepatocellular bile transporters

IL-15 by continuous i.v. infusion to adult patients with solid tumors in a Phase I trial induced dramatic NK cell subset expansion

HSD3B1

A prospective international randomized phase II study evaluating the food effect on the pharmacokinetics (PK) and pharmacodynamics (PD) of abiraterone acetate (AA) in men with castration-resistant prostate cancer (CRPC)

Plasma Protease-Mediated Metabolism of Carfilzomib and Its Implications on Clinical Effects and Side Effects

Aktive Filter

Suchergebnisse filtern